1. Membrane Transporter/Ion Channel
  2. Chloride Channel
  3. Talniflumate

Talniflumate (Synonyms: BA 7602-06)

Cat. No.: HY-103370 Purity: >98.0%
Handling Instructions

Talniflumate (BA 7602-06) is the prodrug of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase. Talniflumate is an orally active Ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome.

For research use only. We do not sell to patients.

Talniflumate Chemical Structure

Talniflumate Chemical Structure

CAS No. : 66898-62-2

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 88 In-stock
Estimated Time of Arrival: December 31
5 mg USD 80 In-stock
Estimated Time of Arrival: December 31
10 mg USD 120 In-stock
Estimated Time of Arrival: December 31
50 mg USD 350 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Talniflumate (BA 7602-06) is the prodrug of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase[1]. Talniflumate is an orally active Ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome[2].

IC50 & Target

IC50: Ca2+-activated Cl- channel (CaCC)[1]

In Vivo

Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CF mice with distal intestinal obstructive syndrome (DIOS)[1]
Dosage: 0.4 mg/g
Administration: Oral chow; 21 days
Result: Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.
Molecular Weight

414.33

Formula

C₂₁H₁₃F₃N₂O₄

CAS No.

66898-62-2

SMILES

O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)OC3OC(C4=C3C=CC=C4)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

TalniflumateBA 7602-06Chloride ChannelCl− Channelscystic fibrosisCFIntestinal diseaseanti-inflammatorychronicobstructivepulmonaryasthmaCOPDanalgesiculcerogenicInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Talniflumate
Cat. No.:
HY-103370
Quantity:
MCE Japan Authorized Agent: